This is a supplement to the January 2019 JAAPA and explores the relationship between type 2 Diabetes (T2D) and cardiovascular disease and is part of AAPA’s curriculum known as Diabetes Leadership Edge.
At the conclusion of this activity, participants should be able to:
Describe the mechanisms by which type 2 diabetes contributes to cardiovascular disease.
Critically appraise the results of cardiovascular outcomes trials of glucose-lowering drugs.
Differentiate glucose-lowering drugs with regard to cardiovascular effects.
Select glucose-lowering strategies for patients in the context of the patient’s overall cardiovascular risk profile.